GLMD Galmed Pharmaceuticals Ltd.

+0  (3%)
Previous Close 5.00
Open 5.08
Price To book 5.48
Market Cap 62.45M
Shares 12,149,000
Volume 26,106
Short Ratio 3.30
Av. Daily Volume 34,527

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b enrollment complettion announced January 9, 2017. Data due 2Q 2018.
Aramchol - ARREST
Non-Alcoholic Steatohepatitis (NASH)
Phase 2 initiated dosing February 2016
Aramchol - ARRIVE
HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD)

Latest News

  1. Galmed Pharmaceuticals to Present at International Liver Congress Data that Shows Aramchol™ has a Potential Direct Effect on Liver Fibrosis
  2. Galmed Pharmaceuticals reports 4Q loss
  3. Galmed Pharmaceuticals Fourth Quarter 2016 Conference Call and Webcast Scheduled for Thursday, March 23rd, 2017
  4. Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study
  5. Galmed Pharmaceuticals Third Quarter 2016 Conference Call and Webcast Scheduled for Monday, November 7th, 2016
  6. Galmed Pharmaceuticals Announces that it has Raised Approximately $5.0 Million to Date Under its ATM Program
  7. 5 Biotech Stocks to Watch as Interest in NASH Increases
  8. These Biotech Names Are on My Radar
  9. Galmed Pharmaceuticals Announces the Appointment of Dr. Liat Hayardeny, Ph.D. MBA, as Chief Scientific Officer
  10. Galmed Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
  11. Galmed Pharmaceuticals Announces the Appointment of Professor Ran Oren, M.D., as Chief Medical Officer
  12. Galmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the Commercialization of Aramchol™ in Korea
  13. Galmed Pharmaceuticals Second Quarter 2016 Conference Call and Webcast Scheduled for Wednesday, August 3rd, 2016
  14. Galmed Pharmaceuticals and Weizmann Institute of Science to enter a research collaboration agreement to assess Aramchol™ effects on microbiome
  15. Galmed Pharmaceuticals Says Ongoing Phase IIB ARREST Trial Expanded To China
  16. Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China